From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...
Physiologically Based Pharmacokinetic Model to Assess the Drug-Drug-Gene Interaction Potential of Belzutifan in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors A total of 14,177 patients were ...
Samsung Medical Center announced that its researchers have developed a new AI model capable of predicting the recurrence risk of non-small cell lung cancer up to a year in advance. According to the ...
Please provide your email address to receive an email when new articles are posted on . The recurrence-free survival estimate at 5 years was 34% in stage III non-small cell lung cancer. Significant ...
At 36 months, the disease-free survival and molecular residual disease event-free rate was 86 vs 36% for patients in the osimertinib and placebo groups. HealthDay News — For patients with resected ...
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, ...
If you smoke and want to quit, call the national quit line at 1-800-784-8669 to speak with a confidential coach. In what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback